These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30233142)

  • 21. Understanding intestinal cysteamine bitartrate absorption.
    Dohil R; Fidler M; Barshop BA; Gangoiti J; Deutsch R; Martin M; Schneider JA
    J Pediatr; 2006 Jun; 148(6):764-9. PubMed ID: 16769383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
    Dohil R; Cabrera BL
    Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.
    Fidler MC; Barshop BA; Gangoiti JA; Deutsch R; Martin M; Schneider JA; Dohil R
    Br J Clin Pharmacol; 2007 Jan; 63(1):36-40. PubMed ID: 17229040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
    Bergonzi E; Herren A; Lavanchy P; Bühlmann C; Wyss SR; Lüthy C; Oetliker O
    Helv Paediatr Acta; 1981 Nov; 36(5):437-43. PubMed ID: 7031022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystinosis: a new perspective.
    Veys KR; Besouw MT; Pinxten AM; Dyck MV; Casteels I; Levtchenko EN
    Acta Clin Belg; 2016 Jun; 71(3):131-7. PubMed ID: 25560059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful use of topical cysteamine formulated from the oral preparation in a child with keratopathy secondary to cystinosis.
    Khan AO; Latimer B
    Am J Ophthalmol; 2004 Oct; 138(4):674-5. PubMed ID: 15488810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cysteamine ophthalmic hydrogel for the treatment of ocular cystinosis].
    Fernández-Ferreiro A; Luaces-Rodríguez A; Díaz-Tomé V; Gil-Martínez M; Rodríguez Ares MT; Touriño Peralba R; Blanco-Méndez J; González-Barcia M; Otero-Espinar FJ; Lamas MJ
    Farm Hosp; 2017 Nov; 41(6):678-687. PubMed ID: 29112493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
    Gahl WA; Balog JZ; Kleta R
    Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%.
    Jones NP; Postlethwaite RJ; Noble JL
    Br J Ophthalmol; 1991 May; 75(5):311-2. PubMed ID: 2036352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy.
    Sonies BC; Almajid P; Kleta R; Bernardini I; Gahl WA
    Medicine (Baltimore); 2005 May; 84(3):137-146. PubMed ID: 15879904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
    Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
    Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
    Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppository formulations as a potential treatment for nephropathic cystinosis.
    Buchan B; Kay G; Matthews KH; Cairns D
    J Pharm Sci; 2012 Oct; 101(10):3729-38. PubMed ID: 22778070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes.
    Clark AM; Pellock JM; Holmay M; Anders B; Cloyd J
    Epilepsy Behav; 2016 Apr; 57(Pt A):105-110. PubMed ID: 26943947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cysteamine in the treatment of cystinosis in children. In vitro and in vivo studies].
    Louis JJ; Guibaud P; Dumoulin R; Parchoux B; Zabot MT; Bureau J; Baltassat P; Frederich A; Larbre F
    Pediatrie; 1984 Dec; 39(8):619-33. PubMed ID: 6535971
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.